follistatin 344 vs cjc+ipa blend
updated
follistatin 344 (tier F) vs cjc+ipa blend (tier A): what each is, why each got its grade, half-life and source counts side by side.
follistatin 344 · tier F
myostatin biology is real. retail injectable follistatin-344 has zero human performance trials and major product-quality concerns.
tier rationale
F-tier because the compound carries multiple overlapping concerns: mechanistic (off-target TGF-β family binding with proliferation implications), clinical (zero human trials, no established safety profile), and market-quality (significant likelihood of product misrepresentation due to synthesis difficulty). Any one of these might keep a compound at D-tier. All three together, plus the absence of a proportionate documented benefit in humans, push it to F. The tier communicates that retail injectable FS-344 does not meet a defensible evidence, safety, or product-quality threshold.
cjc+ipa blend · tier A
clinic-standard GH-axis pairing. cjc-1295 + ipamorelin. receptor logic first, blend trial evidence still thin.
tier rationale
A-tier reflects receptor-pair logic and component-level pharmacology. Not S-tier because direct fixed-blend outcome trials and long-term safety data are missing. The blend is plausible, widely used, and still less proven than the clinic market makes it sound.
at a glance
| follistatin 344 | cjc+ipa blend | |
|---|---|---|
| tier | F | A |
| category | gh / growth | gh / growth |
| sources | 18 | 19 |
| claims evaluated | 6 | 6 |
| half-life | reported variable; reliable PK data in humans for performance doses is absent | CJC-1295: 30 min |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.